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One theory for the pathophysiology of photosensitive
autoimmune skin diseases is that photoinduction of tu-
mor necrosis factor a (TNFa) secretion leads to kerati-
nocyte apoptosis and translocation of previously
sequestered cellular antigens that then activate the im-
mune system. We previously found an association of
the overproducing TNFa-308 A variant with adult der-
matomyositis and with subacute cutaneous lupus er-
ythematosus. Here we focused on mannose binding
lectin (MBL), which is one of several proteins involved
in clearance of apoptotic cells and could thereby lessen
photosensitive autoimmunity. We examined three var-
iant MBL polymorphisms associated with decreased
MBL protein (Asp54, Glu57, and the LX promoter poly-
morphism) in adult dermatomyositis, subacute cuta-
neous lupus erythematosus, and discoid lupus, and
controls. The variant Asp54 allele was positively asso-
ciated with adult dermatomyositis in a dose-responsive
fashion (p¼ 0.0004), as was the Glu57 allele (p¼ 0.004).
None of the three variant MBL alleles considered indi-
vidually was signi¢cantly associated with either suba-
cute cutaneous lupus erythematosus or discoid lupus.
In adult dermatomyositis patients homozygous for the
wild-type TNFa-308G allele (GG), i.e., presumably
without elevated TNFa production, 69% had at least
two of the MBL polymorphisms, versus 20% of healthy
GG controls (p¼ 0.0011). Combinations of low-produ-
cing MBL variants were over-represented in adult der-
matomyositis in a dose-responsive fashion (p¼ 0.0002).
In adult dermatomyositis patients with one variant
TNFa-308 A allele (GA), 46% had at least two MBL
polymorphisms, versus 7% of GA controls (p¼ 0.0077).
Thus, low-producing MBL genes are very strongly as-
sociated with adult dermatomyositis. Our model is that
genetic polymorphisms leading to overproduction of
apoptotic keratinocytes and then impaired clearance of
these cells contribute to the pathogenesis of adult der-
matomyositis, a photoinduced autoimmune skin dis-
ease. Key words: TNFa/apoptosis/lupus/autoimmunity/
photosensitivity. J Invest Dermatol 119:1394 ^1399, 2002
S
everal lines of evidence suggest that photosensitive auto-
immune skin diseases, such as adult dermatomyositis
(DM) and subacute cutaneous lupus erythematosus
(SCLE), develop at least in part from photoinduction of
tumor necrosis factor a (TNFa) secretion, leading to
keratinocyte apoptosis and translocation of previously sequestered
cellular antigens that then activate the immune system (Casciola-
Rosen et al, 1994; Casciola-Rosen and Rosen, 1997). Consistent
with this model, both DM and SCLE exhibit increased numbers
of apoptotic cells in skin biopsies (Pablos et al, 1999). Based on the
model, several classes of abnormalities could contribute to these
diseases: increased production of apoptotic cells, exaggerated im-
mune reactivity to the translocated antigens, and defective clear-
ance of apoptotic cells.We recently reported an association of the
TNFa-overproducing-308 ATNF promoter polymorphismwith
DM (Werth et al, 2002) and SCLE (Werth et al, 2000), the latter
of which was subsequently con¢rmed in other SCLE cohorts
(Millard et al, 2001).We have also found increased activity of the
TNFa promoter with this polymorphism, suggesting that it may
enhance disease by increasing apoptosis in these photosensitive
autoimmune diseases (Werth et al, 2000). Regarding immune re-
activity, SCLE is also associated with HLA-DR3 (Werth et al,
2000), an allele that has been implicated in enhanced anti-Ro/
SSA production (Wilson et al, 1994).
The third possibility, impaired clearance of apoptotic cells, has
received little attention in photosensitive autoimmune disease to
date. Although it is possible that apoptotic cells are simply an
endpoint or marker of disease, recent data in systemic lupus er-
ythematosus patients and autoimmune mouse models suggests
that defects in the clearance of apoptotic cells substantially contri-
bute to triggering autoimmune responses (Sullivan et al, 1996;
Botto et al, 1998; Napirei et al, 2000; Soma et al, 2001; Mitchell
et al, 2002; Scott, 2002). Several proteins, such as mannose-binding
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lectin (MBL), complement factor C1q, surfactant protein A, and
others, have been shown to be involved in the clearance of apop-
totic cells (Korb and Ahearn, 1997; Nepomuceno et al, 1997; Botto
et al, 1998; Tenner, 1998; Navratil et al, 2001; Ogden et al, 2001;
Schagat et al, 2001). MBL has also been shown to be involved in
controlling proin£ammatory cytokines, clearance of immune
complexes, and adhesion molecules on in£ammatory cells, thus
making it particularly relevant in cutaneous autoimmunity (Mas-
caro et al, 1995; Crowson and Magro, 1996; Jack et al, 2001). Low
levels of MBL in humans have been associated with increased
susceptibility to infections (Sumiya et al, 1991; Summer¢eld et al,
1995; Garred et al, 1999). MBL de¢ciencies have been reported in
some systemic lupus erythematosus populations (Davies et al,
1995; 1997; Lau et al, 1996; Ip et al, 1998; Villarreal et al, 2001), but
not others (Horiuchi et al, 2000), and poorer outcomes in early
arthritis are seen in patients with low MBL levels (Ip et al, 2000;
Saevarsdottir et al, 2001).
Importantly, there are several polymorphic sites in the MBL
gene that are known to a¡ect serum concentrations of MBL.
Two are in the MBL promoter region, a wild-type G or a variant
C at position ^550 (designated H for high and L for low, respec-
tively) and a wild-type G or a variant C at position ^221 (desig-
nated Yand X, respectively) (Madsen et al, 1995). These promoter
polymorphisms are in a linkage disequilibrium that limits them
to three haplotypes, HY, LY, and LX, where LX is associated with
the lowest plasma levels of MBL by far. Other known poly-
morphic sites are in exon 1 of the MBL gene at codons 52, 54,
and 57 (Sumiya et al, 1991; Lipscombe et al, 1992; Madsen et al,
2002). These are structural polymorphisms, with single nucleo-
tide substitutions at codon 52 (wild-type Arg to variant Cys), 54
(wild-type Gly to variant Asp), and 57 (wild-type Gly to variant
Glu). The low-producing Asp54 and Glu57 alleles are more preva-
lent, and individuals homozygous for the low-producing variant
at either codon 54 or 57 have almost no circulating MBL in the
serum (Madsen et al, 1995; Crosdale et al, 2000). Heterozygotes
with one low-producing allele at codon 54 or 57 have functional
MBL levels roughly one-eighth of the wild-type phenotype. The
frequencies of these MBL polymorphisms vary amongst ethnic
groups, with both Caucasians and African-Americans having a
similar incidence of the low producing promoter polymorphism
(LX). The Asp54 polymorphism has been found at a gene fre-
quency of 0.19 in England and the codon Glu57 variant was pre-
sent at a gene frequeancy of 0.29 in the Gambian population
(Lipscombe et al, 1992; 1995; 1996; Madsen et al, 1995; 1998; Cros-
dale et al, 2000).
Because the known TNF polymorphism that a¡ects produc-
tion of apoptotic cells and immune reactivity cannot explain all
cases of DM and SCLE, we hypothesized that polymorphisms
related to apoptotic cell clearance might also play a role. There-
fore, we now sought to examine whether genetic polymorphisms
related to MBL are important in the pathogenesis of DM and
SCLE, particularly in cases that have none or only one TNFa-
308 A allele.
MATERIALS AND METHODS
Patients Thirty-four subjects with DM (31 European-Americans, three
African-Americans), 33 with SCLE (32 European-Americans, one African-
American), and 36 with DLE (19 European-Americans, 16 African-
Americans, one Asian Indian) were recruited from the autoimmune
disease cohort in the dermatology practices of authors at the University of
Pennsylvania (V.P.W.) and the University of Louisville (J.P.C.). Written,
informed consent was obtained from each subject. Patients were
diagnosed on the basis of clinical presentation and skin histology,
according to standard criteria (Sontheimer, 1997; 1999; David-Bajar and
Davis, 1997). One hundred and sixty-nine healthy European-Americans
from the same geographic area (Philadelphia) were used as controls for
the DM, SCLE, and Caucasian DLE cohorts. Sixty-seven healthyAfrican-
Americans were used as controls for the strati¢ed African-American DLE
group.
DNA analyses DNAwas isolated from anticoagulated blood according
to standard protocols (PUREGENE, Gentra Systems, Minneapolis, MN).
Genotyping of patients and controls was performed by polymerase chain
reactions (PCR) using allele-speci¢c primers for the MBL (Sullivan
et al, 1996) and TNFa (Vinasco et al, 1997). The alleles of HLA-DR
were determined by a PCR-based method, using sequence-speci¢c
oligonucleotide primers according to the manufacturer’s instructions
(Dynal, Lake Success, NY).
Statistical analysis To determine the importance of the variant allele at
each MBL locus, we used the Kruskal^Wallis test for trend to assess a
possible e¡ect of gene dose (homozygous wild-type versus heterozygous
versus homozygous variant) on disease versus nondisease status. At the
MBL 57 locus, however, there were not enough homozygous variants to
allow this analysis, and so we pooled the few homozygous variants with
the heterozygotes, and then used the Fisher’s exact test to compare disease
cohorts versus controls (2 2 array) (Altman, 1991). Similarly, to determine
the importance of combinations of MBL variant alleles, we used the
Kruskal^Wallis test for trend to assess the e¡ect of the number of MBL
loci involved with a variant polymorphism on disease versus nondisease
status (Altman, 1991). All of the above analyses were performed using
StatXact software. All reported p-values are two-sided (seeTables I^X).
We also tested the interaction between TNFa and MBL by ¢tting
logistic regression models. ‘‘Dose’’ of MBL was treated as an ordinal
variable, with values 1¼GG, 2¼GA, and 3¼AA. TNFa levels were
restricted to GG and GA, because of the sparse data for the AA genotype.
The interaction term was used to test whether the association between
MBL genotype and disease status (case versus control) depended upon the
TNFa genotype.
RESULTS
Association of the Asp54 MBL polymorphism with DM In
the entire DM group, the frequency of the MBL Asp54 allele was
more than double the value in controls, with 62% of patients
homozygous or heterozygous for the low-producing variant
versus 29% of controls (p¼ 0.0004 by Kruskal^Wallis test for
trend; see Table I). There was no statistically signi¢cant increase
Table I. MBL Asp54 polymorphism is over-represented in DM
in a dose-responsive fashiona
Genotype DM SCLE Control (DM, SCLE)
All genotypes 34 (100%) 33 (100%) 167 (100%)
Gly54Gly54 13 (38.2) 20 (66.7%) 119 (71.2%)
Gly54Asp54 17 (50%) 11 (33.3%) 37 (22.2%)
Asp54Asp54 4 (11.8%) 2 (6.1%) 11 (6.6%)
1 or 2 Asp54 alleles 21 (61.8%) 23 (39.4%) 48 (28.8%)
aValues are the number (%) of subjects; p¼ 0.0004, DM versus control, by
Kruskal^Wallis test for trend; p¼ 0.28, SCLE versus control, by Kruskal^Wallis
test for trend. Asp54 polymorphisms are low-producers.
Table II. No signi¢cant increase in prevalence of the MBL
Asp54 polymorphism in DLEa
Genotype DLE
(Caucasian)
Control
(Caucasian)
DLE
(African-
American)
Control
(African-
American)
All genotypes 19 (100%) 167 (100%) 15 (100%) 67 (100%)
Gly54Gly54 16 (84%) 119 (71.2%) 11 (73%) 59 (88%)
Gly54Asp54 1 (5%) 37 (22.2%) 2 (13%) 7 (10%)
Asp54Asp54 2 (11%) 11 (6.6%) 2 (13%) 1 (1.5%)
1 or 2 Asp54 3 (15%) 48 (28.8%) 4 (26%) 8 (11.5%)
ap¼ 0.32, Caucasian DLE versus control, by Kruskal^Wallis test for trend
p¼ 0.14, African-American DLE versus control, by Kruskal^Wallis test for trend.
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seen with SCLE or DLE relative to controls (Tables I, II). To
examine interactions between TNFa and MBL, we re-examined
the MBL Asp54 polymorphism in subjects strati¢ed by TNFa
genotype. (Tables III, IV) There was a highly signi¢cant increase
seen in both ^308 TNF promoter GG and GA, DM patients
(p¼ 0.014 for TNF GG and p¼ 0.0007 for TNF GA, by
Kruskal^Wallis test for trend; see Table III). Nevertheless, the
interaction test was not signi¢cant (p¼ 0.13), despite the
apparently stronger association between MBL and disease status
for DM patients who were also TNF GA.
Association of the Glu57 MBL polymorphism with DM In
the entire DM group, the frequency of the 57 A allele was
increased (0.14 vs 0.04; p¼ 0.004 when tested for anyA;Table V).
No increase in the Glu57 MBL polymorphism was seen with
SCLE (p¼1.00;Table V) or DLE (Caucasians, p¼ 0.67; African-
Americans, p¼ 0.36;TableVI).
Lack of association of the MBL LX promoter poly-
morphism with DM, SCLE, or DLE The incidence of the
low-producing LX allele was no di¡erent in the di¡erent
diseases examined (p¼ 0.55 for DM, p¼ 0.35 for SCLE,
p¼ 0.82 for DLE, by Kruskal^Wallis test for trend; Table VII).
There was an increased homozygosity for LXLX in
African-American DLE patients, giving an overall exact
p¼ 0.0055, but the other statistical tests did not achieve
signi¢cance.
Combinations of polymorphisms and possible gene^gene
interactions To examine possible interactions amongst the
di¡erent MBL polymorphisms, we began by tabulating those
individuals with a variant allele at more than one of the MBL
loci. Within the DM group, 53% of the individuals carried a
variant allele at multiple MBL loci versus 17% of the control
subjects (p¼ 0.0002, by Kruskal^Wallis test for trend; Tables
VIII, IX). There was no increase in combinations of low-
producing MBL polymorphisms in the entire SCLE or DLE
cohorts relative to controls (Tables VIII, IX). To examine
interactions with the TNF ^308 locus, we performed the same
analysis after stratifying individuals by TNF genotype.
Interestingly, 69% of DM TNF ^308 GG patients and 46% of
DM ^308 GA patients had at least two MBL polymorphisms
(compared with 20% and 7% of the corresponding ^308 GG
and GA controls) (p¼ 0.0011 for TNF GG and p¼ 0.0077 for
TNF GA, by Kruskal^Wallis test for trend; Table X). The
interaction between the MBL polymorphisms and TNF was
not signi¢cant (p¼ 0.74) when comparing DM patients to
controls.
When comparing SCLE patients to controls, the interaction
between MBL and TNF was of borderline statistical signi¢cance
(p¼ 0.06), re£ecting the possibility of a stronger association
between MBL and disease status in TNF GA patients, as
opposed toTNF GG patients.
All statistically signi¢cant associations of MBL poly-
morphisms, those related to DM, are listed inTable XII.
Table III. MBL Asp54 MBL polymorphism is over-represented in DM in a dose-responsive fashion even after strati¢cation by
TNFa genotypesa
TNF GG TNF GA TNFAA
Genotype DM Control DM Control DM Control
All Genotypes 18 (100%) 120 (100%) 13 (100%) 43 (100%) 3 (100%) 3 (100%)
Gly54Gly54 6 (33%) 80 (67%) 4 (31%) 35 (81%) 3 (100%) 3 (100%)
Gly54Asp54 10 (55.5%) 30 (25%) 7 (54%) 7 (16%) 0 0
Asp54Asp54 2 (11%) 10 (8.3%) 2 (13%) 1 (8%) 0 0
1 or 2 Asp54 12 (66.5%) 40 (10.8%) 9 (67%) 8 (24%) 0 0
aValues are the number (%) of subjects. p¼ 0.014 for Asp54 mutation in TNF GG DM patients versus controls, by Kruskal^Wallis test for trend; p¼ 0.0007 for Asp54
mutation in TNF GA DM patients versus controls, by Kruskal^Wallis test for trend.
Table IV. No signi¢cant increase in prevalence of the MBL Asp54 polymorphism in subgroups of SCLE patients
de¢ned byTNFa genotypea
TNF GG TNF GA TNFAA
Genotype SCLE Control SCLE Control SCLE Control
All genotypes 11 (100%) 120 (100%) 16 (100%) 43 (100%) 6 (100%) 3 (100%)
Gly54Gly54 7 (64%) 80 (66.7) 9 (56%) 35 (81%) 4 (67%) 3 (100%)
Gly54Asp54 3 (27%) 30 (25%) 6 (37.5%) 7 (16%) 2 (33%) 0
Asp54Asp54 1 (9%) 10 (8.3%) 1 (6.2%) 1 (8%) 0 0
1 or 2 Asp54 4 (36%) 40 (10.8%) 7 (43.7%) 8 (24%) 2 (33%) 0
aValues are the number (%) of subjects. p¼ 0.89 for Asp54 mutation in TNF GG SCLE patients versus controls, by Kruskal^Wallis test for trend; p¼ 0.07 for Asp54
mutation in TNF GA SCLE patients versus controls, by Kruskal^Wallis test for trend.
TableV. MBL Glu57 polymorphism is over-represented in
DM, but not in SCLEa
Genotype DM SCLE Controlw
All genotypes 33 (100%) 35 (100%) 169 (100%)
Gly57 Gly57 24 (72.2%) 33 (94.3%) 155 (91.7%)
Gly57Glu57 9 (27.3%) 2 (5.1%) 14 (8.3%)
Glu57 Glu57 0 0 0
1 or 2 Glu57 9 (27.3%) 2 (5.1%) 14 (8.3%)
aValues are the number (%) of subjects. p¼ 0.004 for presence of variant Glu57
polymorphism, DM versus control, Fisher’s Exact test; p¼1.00 for presence of var-
iant Glu57 polymorphism, SCLE versus control, Fisher’s Exact test.
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DISCUSSION
In the current study, we found that polymorphisms of MBL that
have been associated with low serum levels of MBL are signi¢-
cantly over-represented in DM. Moreover, the Asp54 allele
showed a signi¢cant e¡ect of gene dose (homozygous wild-type
versus heterozygous versus homozygous variant) on disease versus
nondisease status. Combination of polymorphisms were also in-
creased in DM, in a gene dose-responsive fashion, suggesting an
interaction among variant alleles. This e¡ect was evident even
after strati¢cation of subjects byTNFa genotype. Strikingly, most
patients with DM had a variant allele at more than one of the
MBL loci we examined, compared with only one in six of
controls.
Our results provide new support for the concept that autoim-
munity can arise from impaired clearance, as well as overproduc-
tion, of apoptotic cells. The association of multiple di¡erent MBL
polymorphisms with disease suggests that a critical de¢ciency in
the clearance of apoptotic cells is attained by combinations of
low-producing alleles. MBL appears to play a play an important
role in DM relative to SCLE and DLE. This suggests that other
polymorphisms related to the clearance of apoptotic cells, such as
C1q, surfactant protein A, or other collectins, should be evaluated
in photo-induced autoimmune diseases. Associations of poly-
morphisms of certain genes, such as speci¢c collectins, with some
diseases and not others would imply subtle di¡erences in their
function.
Besides impairing the clearance of apoptotic cells, low MBL
levels could exacerbate photoinduced autoimmune diseases
through at least four other mechanisms. First, low MBL levels
have been associated with increased proin£ammatory cytokine
production by monocytes (IL-6 and IL-1b), and high MBL levels
lower TNFa, in addition to the other cytokines mentioned (Jack
et al, 2001). It is possible that similar e¡ects of low MBL levels on
cytokines also contributes to the increased apoptosis observed in
UV-irradiated keratinocytes. Second, immune complexes are
thought to play a role in the muscle disease of DM. In addition,
there is deposition of terminal complement in skin and altera-
tions in vessels consistent with immune complex deposition
(Mascaro et al, 1995; Crowson and Magro, 1996). As MBL plays a
role in clearing immune complexes, it is possible that the de¢-
ciency of MBL contributes to the greater numbers of immune
complexes seen in DM (Walport, 2001; Botto, 2001). Third,
MBL levels a¡ect adhesion molecule expression by in£ammatory
cells, and thus de¢ciency of MBL may increase monocyte adhe-
sion to the vascular system (Jack et al, 2001). Fourth, the incidence
of atypical and bacterial infections is increased in patients with
MBL de¢ciencies (Sumiya et al, 1991; Summer¢eld et al, 1995;
Neth et al, 2000; Turner and Hamvas, 2000). A number of infec-
tions, particularly toxoplasmosis, enterovirus, and Coxsackie B,
have been associated with dermatomyositis, and it is tempting to
speculate that the de¢ciency in this protein due to the low-produ-
cing polymorphisms accounts for both increased infections and
autoimmunity (Kagen et al, 1974; Pollock, 1979; Roig Quilis and
Damjanov, 1982; Bowles et al, 1987; Schroter et al, 1987; Rosenberg
et al, 1989; Harland et al, 1991; Foster et al, 1998; Turner, 1998).
Our results suggest an important role for MBL de¢ciency in
DM. It is likely that the combined abnormality of increased
apoptosis associated with increased cytokines such as TNFa in
combination with delayed clearance of the apoptotic cells contri-
bute to the autoimmunity seen in patients with DM.
TableVI. No signi¢cant increase in prevalence of the MBL Asp54 polymorphism in DLEa
Genotype DLE (Caucasian) Control (Caucasian) DLE (African-American) Control (African-American)
All genotypes 18 (100%) 169 (100%) 16 (100%) 67 (100%)
Gly54Gly54 16 (88%) 155 (91.7%) 10 (62%) 50 (75%)
Gly54Asp54 1 (6%) 14 (8.3%) 4 (25%) 15 (22%)
Asp54Asp54 1 (6%) 0 2 (13%) 2 (3%)
1 or 2 Asp54 2 (12%) 14 (8.3%) 6 (38%) 17 (11.5%)
ap¼ 0.67, for presence of variant Glu57polymorphism, Caucasian DLE versus control, Fisher’s Exact test; p¼ 0.36, for presence of variant Glu57 polymorphism, African-
American DLE versus control, Fisher’s Exact test.
TableVII. No signi¢cant increase in prevalence of the MBL
LX promoter polymorphism in DM or SCLEa
DM SCLE Control
All genotypes 33 (100%) 32 (100%) 168 (100%)
No LX 16 (48%) 20 (62%) 91 (54%)
LX 13 (39%) 10 (31%) 60 (36%)
LXLX 4 (12%) 2 (6%) 17 (10%)
1 or 2 LX 17 (51%) 12 (37%) 77 (46%)
aValues are the number (%) of subjects. p¼ 0.55 for LX variant in DM patients
versus controls, by Kruskal^Wallis test for trend p¼ 0.35 for LX variant in SCLE
patients versus controls, by Kruskal^Wallis test for trend.
TableVIII. Combinations of low-producing MBL variants are
over-represented in DM in a dose-responsive fashiona
Number of MBL loci DM SCLE Control (DM, SCLE)
All subjects 32 (100%) 32 (100%) 166 (100%)
1 26 (81%) 19 (59%) 111 (68%)
2 17 (53%) 8 (25%) 28 (17%)
3 3 (9%) 0 1 (0.6%)
aValues are the number (%) of subjects. p¼ 0.0002 for increased numbers of
MBL polymorphisms in DM versus control, by Kruskal^Wallis test for trend
p¼ 0.92 for increased numbers of MBL polymorphisms in SCLE versus control,
by Kruskal^Wallis test for trend.
Table IX. No signi¢cant increase in prevalence of combina-
tions of MBL polymorphisms in DLEa
Number
of MBL loci
DLE
(European-
American)
Control
(European-
American)
DLE
(African-
American)
Control
(African-
American)
All subjects 19 166 16 67
1 11 (58%) 111 (68%) 12 (75%) 41 (61%)
2 1 (5%) 28 (17%) 1 (6%) 6 (9%)
3 0 1 (0.6%) 1 (6%) 2 (3%)
ap¼ 0.25 for increased numbers of MBL polymorphisms in Caucasian DLE ver-
sus control, by Kruskal^Wallis test for trend; p¼ 0.41 for increased numbers of
MBL polymorphisms in African-American DLE versus control, by Kruskal^Wallis
test for trend.
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of MBL polymorphisms in TNF GA DM patients versus controls, by Kruskal^Wallis test for trend.
TableXI. No signi¢cant increase in prevalence of combinations of MBL polymorphisms in subgroups of SCLE patients de¢ned
byTNFa genotypea
TNF GG TNF GA TNFAA
Number of MBL loci SCLE Control SCLE Control SCLE Control
All subjects 11 120 16 43 5 3
1 6 (54%) 80 (67%) 11 (69%) 28 (65%) 2 (40%) 2 (67%)
2 1 (9%) 24 (20%) 6 (38%) 3 (7%) 1 (20%) 0
3 0 1 (0.8%) 0 0 0 0
ap¼ 0.35 for increased numbers of MBL polymorphisms in TNF GG SCLE patients versus controls, by Kruskal^Wallis test for trend; p¼ 0.13 for increased numbers of
MBL polymorphisms in GA SCLE versus controls, by Kruskal^Wallis test for trend.
TableXII. Summary of statistically signi¢cant associations of MBL polymorphisms
Asp54 MBL polymorphism is increased in DM patients relative to disease-free controls, in a gene dose-responsive fashion (p¼ 0.0004)
Glu57 MBL polymorphism is increased in DM patients relative to disease-free controls (p¼ 0.004)
A larger percentage of DM patients than controls carry MBL polymorphisms at two or more loci, in a gene dose-responsive fashion (p¼ 0.0002). This e¡ect is
evident even after strati¢cation of DM patients and controls into subgroups based onTNF genotype (GG, p¼ 0.0011; GA, p¼ 0.0077).
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